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Abstract
The era of MAO-B inhibitors dates back more than 50 years. It began with Kálmán Magyar’s outstanding discovery of the 
selective inhibitor, selegiline. This compound is still regarded as the gold standard of MAO-B inhibition, although newer 
drugs have also been introduced to the field. It was revealed early on that selective, even irreversible inhibition of MAO-B is 
free from the severe side effect of the non-selective MAO inhibitors, the potentiation of tyramine, resulting in the so-called 
‘cheese effect’. Since MAO-B is involved mainly in the degradation of dopamine, the inhibitors lack any antidepressant 
effect; however, they became first-line medications for the therapy of Parkinson’s disease based on their dopamine-sparing 
activity. Extensive studies with selegiline indicated its complex pharmacological activity profile with MAO-B-independent 
mechanisms involved. Some of these beneficial effects, such as neuroprotective and antiapoptotic properties, were connected 
to its propargylamine structure. The second MAO-B inhibitor approved for the treatment of Parkinson’s disease, rasagiline 
also possesses this structural element and shows similar pharmacological characteristics. The preclinical studies performed 
with selegiline and rasagiline are summarized in this review.
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Introduction
The inhibitors of the catecholamine-degrading enzyme, 
monoamine oxidase (MAO), have long established thera-
peutic use. Deprenyl was first synthesized as a psychic ener-
gizer (Varga and Tringer 1967), tested for antidepressant 
effects and later on characterized as an irreversible MAO 
inhibitor in the 1960s (Knoll et al. 1965). The R-(−)-isomer 
of deprenyl, later called selegiline, was identified as the 
more potent MAO inhibitor (Magyar et al. 1967). In 1968, 
Johnston discovered that the enzyme is heterogeneous and 
the isoform inhibited more potently by clorgyline was named 
MAO-A (Johnston 1968). Magyar and Knoll subsequently 
found that selegiline is also a selective inhibitor, preferen-
tially affecting the other isoform called MAO-B (Knoll and 
Magyar 1972). Because of different substrate specificity and 
tissue distribution of the two isoenzymes, their physiologi-
cal roles differ considerably. The well-known antidepressant 
effect of the previously used non-selective MAO inhibitors 
was found to be the consequence of blocking MAO-A activ-
ity. The irreversible inhibition of MAO-A, however, is also 
responsible for their severe adverse effect, the life-threaten-
ing hypertensive crisis after the consumption of tyramine-
rich meals. This was named ‘cheese effect’ because of the 
high tyramine content of cheese products. Selegiline, in its 
selective MAO-B inhibitory dose, is free from this danger-
ous side effect (Knoll et al. 1968) but also lacks antidepres-
sant activity. As it preferentially reduces the degradation 
of dopamine in the central nervous system (Riederer et al. 
1978), it gained importance in the treatment of Parkinson’s 
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disease from 1975 (Birkmayer et al. 1975, 1977; Parkinson 
Study Group 1993).
The distribution of MAO isoenzymes in the brain was 
extensively studied in post-mortem tissues by Riederer and 
co-workers. MAO-B was shown predominantly in the glia 
(Konradi et al. 1989) and its activity was raised in aged 
patients (Kornhuber et al. 1989). In post-mortem brain stud-
ies, increased dopamine (Riederer and Youdim 1986), and 
especially phenylethylamine levels, (Riederer et al. 1984), 
were found in the nigrostriatal system of selegiline-treated 
parkinsonian patients. Based on these findings, it was sug-
gested that the catecholamine-releasing effect of the elevated 
phenylethylamine may contribute to the dopamine-sparing 
activity of selegiline (Reynolds et al. 1978; Youdim and 
Riederer 1993).
Since it was found that selegiline was able to reduce oxi-
dative stress (Cohen and Spina 1989) and prevent the dopa-
mine-depleting effect of the neurotoxin 1-methyl-4-phenyl-
1,2,3,6-tetrahydropyridine (MPTP) (Langston et al. 1984; 
Cohen et al. 1984), further studies were initiated to clarify 
its pharmacological properties. The results of these experi-
ments indicated possible MAO-B inhibition-independent 
neuroprotective, antiapoptotic, neurorescue activities, and 
the importance of the propargylamine moiety in these 
effects. About 30 years later, rasagiline, another MAO-B 
inhibitor with propargylamine structure, was introduced into 
the therapy of Parkinson’s disease. The pharmacological 
studies aiming to understand the neuroprotective, antiapop-
totic and neurorescue effects of these two drugs are reviewed 
and discussed in this paper.
Protective effect of selegiline 
against neurotoxins
The dopaminergic neurotoxin, MPTP, was discovered acci-
dentally when rapid onset and severe Parkinson’s syndrome 
developed in a drug addict using an in-house synthesized 
pethidine analogue. Later on, the nigrostriatal damage 
induced by the compound was also confirmed (Davis et al. 
1979). It was soon found that MAO-B inhibitors, pargyline 
and selegiline, prevented MPTP toxicity, suggesting the 
involvement of MAO-B in the conversion of pro-toxin 
MPTP to its active form, 1-methyl-4-phenyl-pyridinium 
 (MPP+) (Langston et al. 1984; Cohen et al. 1984). Subse-
quently, it was also shown that  MPP+ generated by MAO-B 
can enter into and damage dopaminergic neurons and is 
responsible for MPTP toxicity. Besides MAO inhibitors, 
dopamine uptake blockers also provided protection, indi-
cating the prominent role of this transporter in the selec-
tive accumulation of the toxin (Fuller and Hemrick-Luecke 
1985).
In following studies, the efficacy of selegiline against the 
active toxin  MPP+ was analyzed in various experimental 
designs. First, Mytilineou and Cohen reported that selegiline 
pretreatment prevented the dopamine depletion induced by 
 MPP+ in rat embryonic midbrain neuronal culture (Mytili-
neou and Cohen 1985). On the other hand, this effect was 
not confirmed in the study by Vaglini et al. (1996). The 
results of the in vivo animal experiments were also con-
troversial; failure, partial effect, and prevention of deple-
tion by selegiline were reported alike (Bradbury et al. 1985; 
Mihatsch et al. 1988; Vizuete et al. 1993). In these studies, 
the  MPP+-induced toxicity was followed by striatal dopa-
mine depletion, but this did not necessarily correspond to 
the dopaminergic cell loss.
MPP+ was identified as a mitochondrial toxin in dopa-
minergic neurons (Nicklas et al. 1985; Heikkila et al. 1985). 
It inhibits the activity of Complex I of the electron transport 
chain (Nicklas et al. 1987) which results in compromised 
energy production (Mizuno et al. 1987) and increased oxi-
dative stress (Cleeter et al. 1992). Similar alterations can 
be induced by the decreased Complex I expression found 
in post-mortem Parkinsonian brain (Mizuno et al. 1989; 
Schapira et al. 1989; Reichmann and Riederer 1989) along 
with its increased iron content (Sian-Hülsmann et al. 2011) 
causing significant oxidative damage. An additional source 
of enhanced oxygen free radical generation is the auto-oxi-
dation of the enormous amount of dopamine released after 
toxin-induced cell damage. The suggested components of 
the protective effect of MAO-B inhibitors against MPTP 
toxicity are summarized in Fig. 1.
To obtain further information about the supposed protec-
tive effect of selegiline, the involvement of its suggested 
antioxidant properties (Cohen and Spina 1989; Gotz et al. 
1995) was studied. Although inhibition of MAO-B itself 
reduces hydrogen peroxide production, other components 
of its antioxidant activity were also hypothesized. As early 
as 1989 Knoll reported that chronic selegiline treatment of 
aged rats enhanced the activity of superoxide dismutase 
in the striatum (Knoll 1989). This was later confirmed by 
Carillo et al. in young animals, as well. Furthermore, in 
addition to superoxide dismutase, increased catalase activ-
ity was also observed (Carrillo et al. 1991). In another study, 
increased antioxidant enzyme activity after selegiline treat-
ment could only be measured in the striatum of aged rats. 
Besides the antioxidant enzymes, the level of glutathione 
was found to be elevated. No effect was detected in the cor-
tex or hippocampus or any brain regions of young animals 
(Takahata et al. 2006). In in vitro cell culture experiments, 
it was shown that selegiline treatment, similar to nerve 
growth factor (NGF), dose-dependently induced superox-
ide dismutase mRNA expression. Selegiline also potentiated 
the effect of NGF, which suggests its action on superoxide 
dismutase mRNA induction is NGF-independent (Li et al. 
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1998). This is in line with the findings of Thiffault et al., 
who found selegiline inhibited oxygen consumption of iso-
lated mitochondria and suggested that this impairment can 
induce an adaptive increase in superoxide dismutase activity 
(Thiffault et al. 1997). However, the antioxidant property 
due to the induction of antioxidant enzymes develops slowly 
following chronic treatment and thus cannot fully explain 
the rapid neuroprotective effect of selegiline. Its acute effect 
on  MPP+-induced hydroxyl radical formation was reported 
without significant influence on dopamine overflow, sug-
gesting the crucial role of direct antioxidant activity (Wu 
et al. 1993). This was supported by the similar effect of 
other hydroxyl radical scavengers and antioxidants (Wu et al. 
1996; Khaldy et al. 2000). Reduced lactate release, a marker 
of hypoxia, from  MPP+-damaged neurons treated with sele-
giline is also indicative of its protective effect (Matsubara 
et al. 2001). Selegiline could also protect nigral neurons 
against other types of oxidative stress-inducing agents, like 
rotenone and iron overload (Saravanan et al. 2006; Budni 
et al. 2007; de Lima et al. 2005), further supporting the 
importance of its antioxidant property.
Selegiline was found to provide protection against other 
monoamine-depleting neurotoxins, as well. DSP-4 (N-(2-
chloroethyl)-N-ethyl-2-bromobenzylamine hydrochloride) 
is selectively accumulated in noradrenergic nerve terminals 
and thus specifically reduces noradrenaline levels in several 
brain regions. Furthermore, it also decreases dopamine-beta-
hydroxylase activity in the brain, consistent with the degen-
eration of noradrenergic neurons (Ross 1976). The protective 
effect of the MAO-B inhibitor selegiline and the non-selec-
tive inhibitor pargyline against DSP-4-induced noradrena-
line depletion was reported, while the MAO-A inhibitor 
clorgyline was found ineffective (Gibson 1987). This sug-
gested the role of MAO-B inhibition in protection. Later, 
however, the structurally unrelated and selective MAO-B 
inhibitor, MDL 72974, failed to prevent DSP-4 toxicity, indi-
cating another mechanism in the protective effect of sele-
giline (Finnegan et al. 1990). As DSP-4 accumulates in the 
noradrenergic terminals by uptake transporters, their inhibi-
tion by selegiline and/or its metabolites was also proposed 
(Magyar et al. 1996, 1998; Magyar and Haberle 1999). How-
ever, the metabolites, R-(−)-methamphetamine and R-(−)-
amphetamine, possessing stronger uptake inhibitory activity, 
showed weaker protection compared to selegiline against 
DSP-4 induced noradrenaline depletion in the hippocam-
pus. Uptake inhibition thus cannot be the sole mechanism 
responsible for the protective effect (Haberle et al. 2001). 
Similarly, selegiline was also found to be protective against 
6-hydroxy-dopamine and 3,4-methylenedioxy-methamphet-
amine, other toxins causing biogenic amine depletion, but 
the exact mechanism of action has not yet been clarified 
(Salonen et al. 1996; Sprague and Nichols 1995).
Although these toxins are very useful in modelling some 
aspects of Parkinson’s disease, their effect is far from the 
pathophysiology of the disorder. Later, other neuronal 
insults, probably more closely related to the pathomecha-
nism of neurodegenerative disorders, were used to study the 
protective effect of selegiline.
Protective effect of selegiline in models 
of neuronal degeneration
NMDA receptor-mediated excitotoxicity is one of the mech-
anisms participating in neuronal death. Selegiline and its 
metabolite desmethylselegiline prevented NMDA-induced 
neurotoxicity in cultured dopaminergic mesencephalic neu-
rons. Desmethylselegiline was actually found to be more 
potent in this test than its parent compound, suggesting 
the contribution of this metabolite to the neuroprotective 
Fig. 1  Targets of selegiline and rasagiline in MPTP toxicity
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effect of selegiline (Mytilineou et al. 1997a, b). Protection 
against NMDA toxicity was also demonstrated in hippocam-
pal slices, and at the same time, it was also shown that the 
drug did not interfere with the NMDA-dependent long-term 
potentiation process (Niittykoski et al. 2003). In an in vivo 
experiment, retinal damage was induced by intravitreal 
NMDA injection. Parenteral, but not local, selegiline admin-
istration was found to be protective, while local desmethylse-
legiline was also effective. This finding further indicates the 
possible contribution of the metabolite desmethylselegiline 
to the neuroprotective effect (Takahata et al. 2003).
It was also shown that selegiline can protect mitochondria 
against pro-oxidant-induced damage. It prevented swelling, 
collapse of membrane potential and cytochrome c release. 
Direct interaction and inhibition of some components of the 
mitochondrial permeability transition pore were proposed 
(De Marchi et al. 2003).
Protein aggregation and the formation of deposits are 
hallmarks of several neurodegenerative disorders. In Par-
kinson’s disease, α-synuclein is the main component of 
the characteristic Lewy bodies. In an in vitro experiment, 
selegiline was shown to modify the aggregation process 
resulting in the formation of large non-toxic aggregates 
(Braga et al. 2011). The structure of selegiline-bound alpha-
synuclein is probably more compact. A similar effect of its 
metabolite, methamphetamine was also reported (Kakish 
et al. 2015). In a mouse study, selegiline reversed the cogni-
tive deficit induced by amyloid beta-peptide in both acute 
and subchronic dosing schedules (Pazini et al. 2013).
Ischemia–reperfusion is a well-established model of neu-
ronal injury and degeneration that is most closely related to 
brain infarction in stroke. Chronic selegiline pretreatment 
effectively reduced the infarct size after transient brain 
ischemia (Knollema et al. 1995). Besides the infarct size, 
the markers of apoptosis, cleaved caspase and DNA frag-
mentation, were also significantly decreased (Unal et al. 
2001). Ischemia-induced lipid peroxidation and memory 
deficit were also alleviated (Maia et al. 2004). Combina-
tion treatment with selegiline and Ginkgo biloba extract was 
more effective in preventing ischemia-induced neuronal loss 
(Kwon et al. 2004). However, pretreatment applied shortly 
before or after global forebrain ischemia was ineffective in 
preventing cell death (Ballabriga et al. 1997).
Neurorescue activity of selegiline
Selegiline studies gained a new impetus from the reports 
of Tatton and co-workers that it effectively rescued dying 
neurons in delayed administration protocols. MPTP admin-
istration to mice induced about 40% decrease in the tyrosine-
hydroxylase positive cell count in the substantia nigra over 
20 days. Selegiline treatment started 72 h after the toxin 
reduced cell loss to about 15% (Tatton and Greenwood 
1991). The rescue effect of selegiline was also observed in 
primary mesencephalic neuronal and glial co-culture. Sele-
giline was administered 24 h after  MPP+ insult and increased 
the dopamine level, TH positive cell and astrocyte count in 
the cultures (Koutsilieri et al. 1994, 1996). Rescue effect was 
shown on non-dopaminergic neurons after axotomy of facial 
motor neurons as well. The authors suggested that selegiline 
could compensate the loss of target-derived trophic support 
(Salo and Tatton 1992). In their further detailed study on 
mutant mice with inherited motor neuron degeneration, sele-
giline failed to show protection (Oh et al. 1994). The neuro-
rescue effect was also observed in a rat model of traumatic 
brain injury, where selegiline improved cognitive functions 
although motor functions remained unchanged. Consistent 
with the symptomatic effect, the injury-induced loss of DBH 
positive cells in the hippocampus was reduced (Zhu et al. 
2000). The kainite-induced hippocampal cell loss and the 
consequent behavioral changes were also affected by sele-
giline treatment. As the improvement remained after cessa-
tion of selegiline dosing, the neurorescue rather than symp-
tomatic effect is confirmed (Gelowitz and Paterson 1999).
The influence of selegiline on trophic factor production 
was extensively examined. One of the first reports showed 
that subchronic selegiline treatment potentiated the lesion-
induced production of basic fibroblast growth factor (bFGF) 
and glial fibrillary acidic protein (GFAP) in rat neostriatum 
(Biagini et al. 1994). Potentiation of cAMP-induced bFGF 
mRNA elevation in rat cortical astrocytes was also shown 
(Riva et al. 1997). The increased production of other neu-
rotrophic factors; NGF, brain-derived neurotrophic factor 
(BDNF), and glia-derived neurotrophic factor (GDNF), in 
cultured mouse astrocytes 24 h after high-dose selegiline 
and desmethylselegiline treatment was also demonstrated 
(Mizuta et al. 2000). In addition to increasing the release of 
neurotrophic factors from astrocytes, its possible effect on 
activated microglia-related neuronal damage was also pro-
posed and studied in a model system. Neuroblastoma cells 
were treated with conditioned media of activated monocytic 
THP-1 cells. Selegiline treatment of the monocytes, but not 
the neuroblasts, dose-dependently prevented the damage of 
the latter. Other examined MAO inhibitors were ineffective, 
confirming the suggested MAO-independent mechanism 
(Klegeris and McGeer 2000). Selegiline-induced enhanced 
NGF production and the consequent protection against exci-
totoxic and ischemic damage of neurons were reported in 
a thorough study. In the in vitro cell culture experiment, 
increased NGF production was demonstrated in response to 
a rather low (10 pM–1 nM) selegiline concentration. Moreo-
ver, increased production of NGF was also shown in the 
cerebral cortex of rats after intraperitoneal administration 
of selegiline accompanying the protection against ischemic 
insult (Semkova et al. 1996).
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Furthermore, in cultured dopaminergic neurons, it was 
also shown that neurite length was similarly increased by 
selegiline and BDNF, although selegiline increased the 
average neuritic branch length, while the formation of new 
branches was increased by BDNF (Kontkanen and Castren 
1999). Consistent with its neurotrophic factor inducing and/
or mimicking effect, selegiline induced the differentiation of 
various stem cells into neuron phenotype. In these in vitro 
experiments, selegiline was typically found effective in a 
low concentration (around  10−8 M) that cannot consider-
ably inhibit MAO-B activity. Increased neurotrophic factor 
expression and differentiation to neurons were demonstrated 
in embryonic stem cells (Esmaeili et al. 2006), bone-marrow 
stromal cells (Ghorbanian et al. 2010), embryonal carci-
noma stem cells (Bakhshalizadeh et al. 2011), and neural 
stem cells (Hassanzadeh et al. 2015) following selegiline 
treatment.
Antiapoptotic activity of selegiline
After revealing that selegiline can induce the synthesis of 
neurotrophic factors and antioxidant enzymes, it was sug-
gested that its neuroprotective-neurorescue effect is based 
on a complex action on the regulation of cell survival 
mechanisms (Tatton and Chalmers-Redman 1996; Magyar 
et al. 2006). In differentiated PC12 cells, selegiline and its 
metabolite desmethylselegiline modified the serum and NGF 
withdrawal-induced expression of several genes. In addition 
to the previously reported increase in antioxidant enzymes, 
superoxide dismutase and glutathione peroxidase, altered 
expression of other apoptosis-related proteins was also 
observed. It prevented the elevation of c-JUN and GAPDH 
and the reduction of BCL-2 levels, as well as the mitochon-
drial translocation of BAX. All these changes may result in 
an antiapoptotic effect by maintaining mitochondrial mem-
brane potential and preventing the opening of permeability 
transition pores (Tatton and Chalmers-Redman 1996). On 
cerebellar granule cells, selegiline and another propargyl 
compound prevented the impaired mitochondrial function 
related to apoptosis without affecting low potassium-induced 
apoptotic cell death. These findings further confirmed that 
selegiline selectively inhibits the mitochondrial route of 
apoptosis (Paterson et al. 1998). The effect of selegiline and 
the related propargylamines was dose dependent; the maxi-
mal antiapoptotic effect developed at a concentration level 
of  10−9 M. Further concentration increase was accompa-
nied by a decline in the effect (Tatton et al. 2002). This low 
concentration of selegiline was previously found effective 
in preventing okadaic acid-induced apoptotic response in 
cultured hippocampal and cerebellar granule cells, as well 
as in Neuro-2a neuroblastoma cells. However, selegiline did 
not provide protective activity against serum withdrawal in 
these model cells (Suuronen et al. 2000). Contrary to this 
finding, selegiline in submicromolar concentration prevented 
apoptotic cell death induced by either serum deprivation 
or hypoxia in cultured retinal neurons (Xu et al. 1999). In 
another study, a similar low selegiline dose could delay 
the serum deprivation evoked excessive apoptosis in two 
melanoma cell lines of neuroectodermal origin by 2 days, 
while its enantiomer pair, S-(+)-deprenyl was ineffective. 
In this study high, millimolar, doses of selegiline and des-
methylselegiline were shown to increase apoptotic cell death 
even without serum withdrawal (Szende et al. 2000). These 
findings confirmed the bell-shaped dose dependence of 
the antiapoptotic effect, indicating the importance of care-
ful experimental design and reconsideration of the dosing 
schedule of selegiline (Magyar et al. 2004; Magyar 2011).
The antiapoptotic effect of selegiline and related prop-
argyl compounds was also demonstrated against various 
neurotoxins in in vitro cell culture experiments. It partially 
protected the  MPP+-treated SK-N-SH neuroblastoma cells 
with attenuation of toxin-induced alterations of several apop-
tosis markers, including cytochrome c release and caspase 
3 activation (Sharma et al. 2003; Chetsawang et al. 2008). 
In SH-SY5Y neuroblastoma cells, selegiline pretreatment 
protected the cells against the apoptotic effect of the hypoth-
esized endogenous toxin, N-methyl-R-salsolinol detected by 
a reduction in DNA fragmentation. In addition to the toxin, 
apoptosis induced by reactive oxygen and nitrogen species 
was also studied (Naoi et al. 2000). It is worth mention-
ing that in these experiments on neuroblastoma cells, the 
effective selegiline concentration was much higher, in the 
micromolar range. This discrepancy might be explained by 
the possibly differing nature of differentiated and undiffer-
entiated cells.
In recent studies, the apoptosis-preventing effect of sele-
giline was also reported in various animal experiments. 
Pretreatment with selegiline attenuated the 3-nitropropi-
onic acid-induced striatal and cortical apoptosis demon-
strated by reduced caspase 3 activation and altered BCL-2/
BAX ratio. Furthermore, the toxin-induced behavioral 
changes were also improved (Wahdan et al. 2017). Admin-
istering selegiline following MPTP lesion in mice induced 
an antiapoptotic change in BCL-2 and BAX expression 
besides increased trophic factor production. At the same 
time, the drug rescued the toxin-induced gait deficit (Zhao 
et al. 2013). When administered after focal brain ischemia, 
selegiline reduced the infarct size, induced the antiapop-
totic genes, and promoted NOTCH-JAGGED signaling in 
the astrocytes. It was accompanied by reduced peri-infarct 
edema, likely due to preserving brain microcirculation (Nar-
dai et al. 2015). The proposed mechanisms contributing to 
the antiapoptotic activity of selegiline are shown in Fig. 2.
The cytoprotective, antioxidant, and antiapoptotic effects 
of selegiline are not restricted to damaged neuronal cells. 
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In cultured airway epithelial cells, cigarette smoke extract-
induced oxidative stress and inflammation were dose-
dependently reversed by selegiline in the  10−8–10−6 M 
range. The authors suggested that the antioxidant property of 
the drug is also responsible for its anti-inflammatory effect 
through preventing the activation of inflammation-related 
transcription factors Nrf2 and NF-κB (Cui et al. 2017). 
Chronic low-dose selegiline was shown to increase the total 
scavenger capacity of plasma and prevent the fat-rich diet-
induced increase in the liver fat content (Bekesi et al. 2012). 
Renal cells could also be rescued from hypoxia-induced 
apoptotic death in an animal study (Toronyi et al. 2002). 
In a rabbit model of cardiac failure, 8 weeks of selegiline 
treatment improved left ventricular function by rescuing 
myocytes from apoptosis (Qin et al. 2003).
The beneficial effect of selegiline on aging has also 
been reported in several papers since the first one pub-
lished by Birkmayer et al. (1985). Chronic treatment with 
selegiline considerably increased the lifespan of rats and 
also improved the sexual activity (Knoll 1988; Knoll et al. 
1989) and learning performance of aged animals (Cara-
georgiou et al. 2003). As potential mechanisms responsible 
for longevity induction, its antioxidant, cytoprotective, and 
neuronal activity stimulating, so-called enhancer effect on 
monoaminergic transmissions, are suggested (Knoll and 
Miklya 1994; Kaur et al. 2003; Singh et al. 2012; Kitani 
et al. 2002).
During the studies on the neuroprotective effect of sele-
giline, it emerged that the pharmacophore includes the pro-
pargylamine moiety. This was supported by the observed 
activity of its desmethyl metabolite. However, desmethyl-
selegiline was shown to be a minor metabolite, representing 
less than 1% of the administered dose (Szökő et al. 2004b). 
Other aromatic and aliphatic propargyl compounds with or 
without MAO inhibitory activity were also examined. Their 
effects in in vitro and in vivo antiapoptotic and neuroprotec-
tive tests were similar to those of selegiline (Paterson et al. 
1998; Waldmeier et al. 2000a, b).
Fig. 2  Putative targets of selegiline and rasagiline involved in their effects independent of MAO-B enzyme inhibition
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Neuroprotective and neurorescue effects 
of rasagiline
Besides selegiline, several propargyl compounds were syn-
thesized and studied in the 1970s for their MAO inhibitory 
effect. Among these, an aminoindane structure, J-508, was 
found to be about ten times more potent an inhibitor of 
MAO-B, although its selectivity for MAO-B over MAO-A 
inhibition was not better than that of selegiline (Magyar 
et al. 1979; Magyar 1994). The desmethyl derivative of this 
compound, rasagiline, was developed later as the second 
MAO-B inhibitor approved for the treatment of Parkinson’s 
disease. Its neuroprotective and neurorescue effects were 
also extensively studied.
Initially, in vitro and in vivo tests, similar to those previ-
ously done with selegiline, were performed with rasagiline 
to demonstrate its neuroprotective, antioxidant, antiapop-
totic, and neurorescue effects. Similar to selegiline, it was 
found effective against various neurotoxins. It increased the 
survival of dopaminergic neurons in the substantia nigra and 
the stereotypical behavior induced by 6-hydroxydopamine 
(Blandini et al. 2004). In in vitro experiments on SH-SY5Y 
cells, the inhibition of toxin-induced mitochondrial impair-
ment-related apoptosis was demonstrated as a mechanism 
of the protective effect. Similar results were reported when 
peroxynitrite donating SIN-1 or N-methyl-(R)-salsolinol 
were used to induce neuronal damage (Maruyama et al. 
2000a, 2001b). Rasagiline showed neurorescue activity 
when administered chronically to post-MPTP-lesioned mice. 
It increased dopaminergic cell survival in the midbrain by 
upregulation of the tyrosine kinase receptor (Trk)–phos-
phatidylinositol 3 (PI3) kinase–Akt pathway (Weinreb et al. 
2006; Sagi et al. 2007). It also reduced the degeneration of 
neurons in the paraventricular nucleus of the hypothalamus 
in spontaneously hypertensive rats in a dose-dependent man-
ner. This effect was accompanied by a reduction in blood 
pressure. The antihypertensive medications, captopril and 
hydralazine, were ineffective in preventing neurodegenera-
tion, suggesting direct neuroprotection by rasagiline as a 
primary effect (Eliash et al. 2005).
The induction of catalase and superoxide dismutase (anti-
oxidant enzymes) activities by chronic rasagiline treatment 
in substantia nigra and striatum, but not in hippocampus, 
was demonstrated. Interestingly, the activity of the enzymes 
also increased in peripheral tissues, kidney, and heart (Car-
rillo et al. 2000). Similar to selegiline, it was proven effective 
against ischemic insults. In NGF-differentiated PC12 cells, it 
protected against oxygen–glucose deprivation-induced cell 
death (Abu-Raya et al. 1999). In an in vivo animal study, it 
reduced the infarct size and improved the neurological and 
cognitive functions when administered after middle cerebral 
artery occlusion (Speiser et al. 2007). In a cell-culture model 
overexpressing alpha-synuclein, the use of paraquat-induced 
significant oxidative stress and caspase 3 activation that 
was prevented by rasagiline (Chau et al. 2010). In another 
in vitro model, rasagiline attenuated microglia activation-
related oxidative stress and pro-inflammatory cytokine 
release, features that may contribute to its neuroprotective 
properties (Trudler et al. 2014).
The mechanism of neuroprotective-antiapoptotic effect of 
rasagiline was extensively studied in cell culture experiments 
mainly using SH-SY5Y dopaminergic neuroblastoma cells. 
Induction of neurotrophic factors, mainly GDNF (Maruyama 
et al. 2002a, 2004) and antiapoptotic BCL protein family 
members (Akao et al. 2002b; Inaba-Hasegawa et al. 2012) 
were reported. Probably, these contribute to protection of 
mitochondrial integrity and prevention of mitochondrial per-
meability transition pore opening which were also demon-
strated (Maruyama et al. 2000b, 2002b; Wu et al. 2016). The 
importance of mitochondrial protection in the antiapoptotic 
effect was also confirmed in cerebellar granule cells, where 
rasagiline prevented cytosine beta-d-arabinofuranoside, 
l-buthionine-(S,R)-sulfoximine, or glutamate but not low 
potassium or serum deprivation-induced apoptosis (Bonneh-
Barkay et al. 2005).
Prevention of mitochondrial depolarization and the open-
ing of permeability transition pores by rasagiline were also 
reported using isolated mitochondria suggesting a direct 
mitochondrial target (Akao et al. 2002a). Prevention of 
nuclear translocation of GAPDH was also demonstrated and 
the enzyme was suggested as another possible target for pro-
pargylamine compounds (Maruyama et al. 2001a; Ou et al. 
2009; Waldmeier et al. 2000b). Chronic rasagiline treatment 
was shown to increase the expression and activation of pro-
tein kinase C and, at the same time, to beneficially affect 
amyloid processing (Bar-Am et al. 2004). In a cell culture 
study, this effect was shown dependent on alpha-secretase 
activity and protein kinase C and ERK kinase signaling. A 
similar effect of the non-MAO inhibitor S-enantiomer of 
rasagiline was also demonstrated, indicating that the protec-
tion is unrelated to MAO-B inhibition but dependent on the 
propargylamine structure (Yogev-Falach et al. 2003).
Safinamide, the reversible MAO‑B inhibitor
Recently, a third MAO-B inhibitor, safinamide was also 
introduced into the therapy. It has a different chemical 
structure and pharmacological properties compared to sele-
giline and rasagiline. In isolated rat brain mitochondria, it 
potently and reversibly inhibits MAO-B with an IC50 value 
of 98 nM, while its potency on MAO-A is about 5000 times 
lower (Caccia et al. 2006). In line with these in vitro results, 
it provides complete MAO-B inhibition in 0.6 mg/kg single 
dose without affecting MAO-A activity in humans (Marzo 
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et al. 2004). Besides MAO-B inhibition, it was found to 
block voltage-dependent sodium and N-type calcium chan-
nels, although in much higher concentrations. In in vitro 
experiments, the difference between IC50 values of chan-
nels blocking and MAO-B inhibition was 2–3 orders of 
magnitude. As a consequence of its effect on ion channels, 
it also inhibits the release of glutamate (Caccia et al. 2006; 
Fariello 2007).
Neuroprotection by safinamide was also studied. It 
prevented the MPTP-induced toxicity consistent with its 
MAO-B inhibitory effect and its weak dopamine uptake 
inhibitor activity (Fariello 2007) may also contribute. Four 
hours after MPTP insult, it failed to affect dopamine deple-
tion; however, some sparing effect on dopaminergic neu-
rons was observed. In pretreatment, it also alleviated neu-
ron loss induced by kainate. The neurodegeneration induced 
by ischemia was also reduced by both pre- and post-insult 
treatment (Caccia et al. 2006). These protective effects were 
reported at high safinamide doses, indicating the probable 
role of its channel blocking property and the consequential 
inhibition of glutamate release. Clinical properties of safina-
mide along with those of the irreversible MAO-B inhibitors 
were recently reviewed (Dezsi and Vecsei 2017).
There is continuous interest in studying reversible 
MAO-B inhibitors. In addition to safinamide, several other 
natural and synthetic compounds were reported as reversible 
MAO-B inhibitors and examined in preclinical and early 
clinical studies. Sembragiline, a compound structurally 
related to safinamide, is a highly selective MAO-B inhibi-
tor with long lasting effect (Borroni et al. 2017). Its pos-
sible beneficial effect in moderate Alzheimer’s disease has 
recently been evaluated in a phase 2 clinical trial without 
conclusive results (Nave et al. 2017). In preclinical stud-
ies, not only further biaryl compounds (Yeon et al. 2018), 
but new chemical structures, like furanochalcones (Suresh 
et al. 2018) are also being investigated. Among natural 
compounds, chrysin was reported having MAO-B inhibi-
tory activity, besides several other pharmacological effects 
resembling to those of selegiline and rasagiline (Guo et al. 
2016).
Comparison of the effects of selegiline 
and rasagiline
The majority of the reported effects of rasagiline are similar 
to those previously published with selegiline. Some direct 
comparative studies were performed, as well. Prevention 
of MPTP-induced neurotoxicity was compared in monkeys 
and their effects were found similar in terms of biochemi-
cal, histological, and behavioral means. As MAO-B inhibi-
tion significantly contributes to the reduced MPTP toxicity, 
this result could be expected (Kupsch et al. 2001). In vitro 
survival of tyrosine-hydroxylase positive neurons was selec-
tively improved by both MAO-B inhibitors at the relatively 
high concentration of 1–10  µM. The MAO-A inhibitor 
clorgyline and R-(−)-methamphetamine, had no effect on 
cell viability in this concentration range. The survival of 
GABAergic neurons was not affected by any examined com-
pounds (Finberg et al. 1998; Goggi et al. 2000). Rasagiline 
and selegiline similarly inhibited  Ca2+ efflux from mito-
chondria after opening of the mitochondrial permeability 
transition pores and attenuated superoxide generation (Wu 
et al. 2015). Using hippocampal slices, it was observed that 
glutamate-mediated excitotoxicity was attenuated by both 
rasagiline and selegiline; however, more detailed analysis 
revealed different mechanisms, i.e., modulation of different 
glutamate receptor responses (Dimpfel and Hoffmann 2011). 
In an in vivo study of focal cerebral ischemia, rasagiline in 
3 mg/kg dose, but not in 1 mg/kg, accelerated the sympto-
matic recovery, while the final neurological scores were not 
improved. At the same time, it reduced the infarct size. Sele-
giline in the same dose did not show these effects. Higher 
doses were not examined; thus, the ineffectiveness may have 
been caused by the well-known potency difference between 
the two drugs (Speiser et al. 1999). In another in vivo model 
of neurodegeneration using ubiquitin–proteasome system 
inhibitor lactacystin, selegiline and rasagiline pretreatment 
were effective alike. When treatment started after the insult, 
selegiline was found less effective (Zhu et al. 2008).
Some of the studies also aimed to evaluate the influence 
of their metabolites on the protective effect. Some selegiline 
metabolites keep the propargylamine structure. The neuro-
protective effect of desmethylselegiline was observed in 
various tests, including demonstration of its beneficial effect 
against NMDA toxicity (Mytilineou et al. 1997b; Takahata 
et al. 2003) and in inducing the production of neurotrophic 
factors (Mizuta et al. 2000) and antiapoptotic proteins (Tat-
ton and Chalmers-Redman 1996). Its N-oxide metabolite 
was only identified later (Katagi et al. 2001; Tabi et al. 
2003; Szökő et al. 2004b) because of shortcomings in the 
previously used analytical method, gas chromatography. The 
neuroprotective effect of selegiline-N-oxide against DSP-4 
induced noradrenaline depletion was found to be compara-
ble with that of the parent compound (Szökő et al. 2004a). 
The main non-propargyl metabolites of selegiline are 
R-(−)-methamphetamine and R-(−)-amphetamine (Szoko 
et al. 1999; Tabi et al. 2003; Shin 1997), while rasagiline is 
converted to 1-R-aminoindan (Siddiqui and Plosker 2005). 
Since S-enantiomers of amphetamines have considerable 
psychomotorstimulatory and neurotoxic effects, it was sug-
gested that the metabolites of selegiline may counteract its 
neuroprotective effect. The R-amphetamines, however, are 
much weaker releasers of catecholamines and are formed 
in a rather low concentration during selegiline metabolism 
(Magyar and Tothfalusi 1984; Magyar et al. 2004). In an 
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in vitro cell culture study, a high concentration of meth-
amphetamine did not prevent against serum and NGF 
withdrawal-induced death of PC12 cells and reduced the 
protection by selegiline or rasagiline (Bar Am et al. 2004). 
However, during therapeutic use of selegiline, much lower 
concentrations of amphetamines are formed (Heinonen et al. 
1989), so the counteraction of the selegiline effect is not 
very probable. Data on the effect of 1-R-aminoindane are 
controversial as well. It was found effective in a rather high 
concentration of 1 μM in a model of serum and NGF with-
drawal-induced PC12 cell death (Bar Am et al. 2004) and 
dexamethasone-induced apoptosis of SH-SY5Y neuroblas-
toma and 1242-MG glioblastoma cells (Tazik et al. 2009). 
However, in another test using cerebellar granule cells, it 
was not found effective against various cell insults in the 
wide concentration range studied (Bonneh-Barkay et al. 
2005). Based on these results, the importance of the propar-
gylamine structure in the neuroprotective effect of MAO-B 
inhibitors is rather accepted. This is further confirmed by 
the results that N-propargylamine itself showed neuroprotec-
tive activity against serum withdrawal-induced apoptosis of 
PC12 cells (Weinreb et al. 2005).
Evaluation of neuroprotective effect 
in clinical studies
There were several clinical trials designed to assess the dis-
ease-modifying, neuroprotective effect of the MAO-B inhib-
itors in Parkinson’s disease but without any final conclusion 
(for review and detailed discussion, see Riederer and Laux 
2011). In the DATATOP study, according to the putative 
antioxidant activity, the effect of selegiline and tocopherol 
was evaluated in patients in early phases of the disease with-
out taking other anti-parkinson treatment. The motor scores 
(UPDRS) and daily activity (ADL) were measured and the 
need for initiating levodopa for symptoms control registered. 
Selegiline treatment improved the scores and delayed the 
initiation of levodopa treatment by about 9 months. Tocoph-
erol was not more effective than the placebo. After 2 months 
of selegiline withdrawal, the motor symptoms declined and 
the neuroprotective effect of the drug could not be proven 
(Parkinson Study Group 1993). In the case of rasagiline, a 
differently designed study was performed and revealed that 
the benefit of early initiated rasagiline treatment was main-
tained during the continued treatment period. However, a 
significant difference was only found in the 1 mg/day rasa-
giline dose treatment and not at the higher, 2 mg/day dose 
(Parkinson Study Group 2004). In spite of several re-eval-
uations and post hoc analysis of the clinical trial data, the 
symptomatic and disease-modifying effect of neither drug 
could be unequivocally distinguished.
Conclusions
Although several pharmacological experimental data in 
support of the neuroprotective effect of both irreversible 
MAO-B inhibitors were published, the results of in vitro 
experiments could hardly be translated to a clinical effect. 
Even the preclinical data are inconsistent regarding the 
effective concentrations of the drugs and the suggested role 
of their metabolites, which may be the sources of some 
discrepancies between the findings of in vitro and in vivo 
studies. Some of the preclinical results suggest differences 
between the protective effect of selegiline and rasagiline. 
However, the recent meta-analysis of randomized clinical 
trials (Marconi and Zwingers 2014), drug utilization analysis 
of delaying levodopa prescription in patients on selegiline or 
rasagiline treatment (Peretz et al. 2016), and a head-to-head 
3-year retrospective case–control study (Cereda et al. 2017) 
concluded similar efficacy and neuroprotective potential of 
the two drugs.
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